What question did this study set out to answer?

This research aims to improve therapeutic decision-making for diffuse midline glioma through proteogenomic analysis.

March 14, 2026Neuro-Oncology PediatricsOpen Access

DMG-16. Integrative proteogenomic analysis for improved therapeutic decision-making in diffuse midline glioma

View Full Paper

Ask AI

Bookmark

Authors

IFIzac J. FindlayHunter Medical Research Institute DSDilana E. StaudtHunter Medical Research Institute RDRyan J. DuchatelHunter Medical Research Institute

Discussion

Member takes

Implication

Proteogenomic analysis reveals therapeutic targets and improves overall survival in diffuse midline glioma patients, suggesting precision medicine may benefit treatment strategies.

Key Points

This research aims to improve therapeutic decision-making for diffuse midline glioma through proteogenomic analysis.
Conducted proteogenomic analysis on 210 DMG and pHGG tissue and cell-line samples.
Identified driver alterations in genomic landscapes and characterized proteomes with posttranslational modifications.
Performed proliferation assays and in vivo studies using a patient-derived xenograft model to evaluate therapeutic efficacy.
Preliminary findings highlight driver alterations in genes related to tumor suppression and signaling pathways.
Combination treatments of avapritinib and paxalisib showed improved overall survival compared to monotherapies.
Ongoing studies are testing novel treatment regimens combining RT with ATM inhibition followed by targeted therapies.

Cite This Study

Findlay et al. (2025) studied this question.

synapsesocial.com/papers/69b4b9db18185d8a39802006 https://doi.org/10.1093/neuped/wuaf001.046

View Full Paper

Ask AI

Bookmark

Implication

Proteogenomic analysis reveals therapeutic targets and improves overall survival in diffuse midline glioma patients, suggesting precision medicine may benefit treatment strategies.

DMG-16. Integrative proteogenomic analysis for improved therapeutic decision-making in diffuse midline glioma

Discussion

Member takes

Implication

Key Points

Cite This Study

DMG-16. Integrative proteogenomic analysis for improved therapeutic decision-making in diffuse midline glioma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider